On May 15, 2018 Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, reported that data from preclinical studies of its HER2-targeted CAR-T cell containing its dual-switch technology will be reviewed in an oral presentation at the 21st Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) (Free ASGCT Whitepaper) being held in Chicago, Illinois from May 16-19 (Press release, Bellicum Pharmaceuticals, MAY 15, 2018, View Source [SID1234526611]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The potential of our novel dual-switch CAR-T platform to provide in vivo control over adoptive immunotherapies is very exciting," said Bellicum’s President & CEO Rick Fair. "These data suggest the potential to significantly reduce toxicities while prolonging efficacy using molecular switches activated by small molecule agents. We believe this technology may address some of the major challenges with CAR-T therapies, particularly when targeting solid tumors. We look forward to initiating clinical trials in 2019 with two CAR-T cell candidates engineered with dual switches."

Presentation Details:

Title: HER2-Targeted Dual-Switch CAR-T Cells Enable Post-Infusion Control of CAR-T Efficacy and Safety with Small Molecules
Session: 113 Cancer – Targeted Gene & Cell Therapy I
Date/Time:Wednesday, May 16th11:00 a.m. CDT

The presentation will be made available in the Events and Presentations section of the Bellicum website shortly after the presentation.